Principal Scientist
Genetech
Collegeville, Pennsylvania
Hardik is currently working as a Principal Scientist within the Clinical Pharmacology department at Genentech. In his current role, he supports clinical pharmacology and modeling & simulation strategies for early clinical development programs including cell therapy and T-cell bispecifics from Genentech's portfolio. Previously, he was a Principal Scientist, Translational PK/PD at Janssen R&D where he supported early discovery, preclinical and early clinical development of therapeutic biologics in oncology and other therapeutic areas. He also served as the PK/PD SME (Subject Matter Expert) for cell and gene therapies. He also supported PK/PD modeling and simulation approaches to guide molecule design as well as rational FIH (First-In-Human) human dose selections for novel therapeutic modalities such as T-cell redirectors, monoclonal antibodies, antibody-drug conjugates, and cell and gene therapies. Prior to Janssen, he was a Postdoctoral Associate at Center for Pharmacometrics and Systems Pharmacology at the University of Florida, where he worked extensively on PK/PD approaches for drug combinations in oncology and PBPK modeling of small molecules. Hardik is a Pharmacist and completed his graduate training (M.S. & Ph.D.) in Pharmaceutics from the Ohio State University. He has authored ~20 peer-reviewed scientific journal articles and several scientific abstracts in PK/PD, oncology, and drug delivery.
Symposium: Evolving Clinical Pharmacology and Translational PK/PD Approaches For New Modalities
Tuesday, October 24, 2023
9:00 AM – 11:00 AM ET